| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | N/A | N/A | N/A | N/A | N/A |
| MA10 | N/A | N/A | N/A | N/A | N/A |
| MA20 | N/A | N/A | N/A | N/A | N/A |
| MA50 | N/A | N/A | N/A | N/A | N/A |
| MA100 | N/A | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | N/A | N/A |
| RSI | N/A | N/A | N/A | N/A | N/A |
| STOCH | N/A | N/A | N/A | N/A | N/A |
| WILL %R | N/A | N/A | N/A | N/A | N/A |
| CCI | N/A | N/A | N/A | N/A | N/A |
|
Tuesday, September 08, 2026 09:04 AM
Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in ...
|
|
Monday, August 03, 2026 02:00 AM
Leadership additions enhance clinical, technical and governance capabilities as Korsana advances lead program KRSA-028 for the treatment of Alzheimer's disease Korsana Biosciences, Inc. (“Korsana” or ...
|
|
Monday, August 03, 2026 12:00 AM
WALTHAM, Mass.--(BUSINESS WIRE)--Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/09/26 | 30.85 | 33.75 | 29.377 | 31.61 | 52,100 |
|
|
||||
|
|
||||
|
|